Stocks and Investing
Stocks and Investing
Wed, October 7, 2015
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, October 6, 2015
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, October 5, 2015
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Upgraded (BLUE) to Buy and Held Target at $143 on, Oct 5th, 2015
Matthew Harrison of Morgan Stanley, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Held Target at $143 on, Oct 5th, 2015.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Jason McCarthy of "Maxim Group" Maintained at Strong Buy and Held Target at $190 on, Wednesday, June 17th, 2015
- Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $244 on, Monday, June 15th, 2015
- Matthew Luchini of "BMO Capital" Maintained at Buy with Increased Target to $239 on, Monday, June 15th, 2015